1
|
Ignoffo RJ, Knapp K, Ellis W. Board-certified pharmacy specialties: Growth from 2008 to 2020 and projections to 2025. Am J Health Syst Pharm 2022; 79:2134-2140. [PMID: 36148562 DOI: 10.1093/ajhp/zxac243] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
DISCLAIMER In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time. PURPOSE To track and analyze the growth of 12 Board of Pharmacy Specialties (BPS) specialties from 2008 to 2020 and, subject to criteria, to project specialty numbers through 2025. The analysis considered residency data and Bureau of Labor Statistics projections. METHODS BPS data were used to determine numeric growth, growth rates, and trends for 12 BPS specialties from 2008 to 2020. Specialties begun after 2008 were analyzed from their start date. For specialties with more than 2 data points and coefficients of determination greater than 0.80, we calculated projections through 2025. We also estimated the percentage of BPS-certified pharmacists with postgraduate year 1 training. RESULTS BPS-certified pharmacists grew in number from 3,004 (2008) to 41,802 (2020), an over 13-fold increase. Currently, 4 of the 5 largest specialties (pharmacotherapy, ambulatory care, oncology, and critical care) continue to grow at a fast rate. Pharmacotherapy experienced the largest numeric growth (20,624) despite the ongoing introduction of new specialties. Critical care and infectious diseases had the highest growth rates (both 32%). We were able to make projections for 10 of 12 specialties, with greater than 62,000 certifications projected by 2025. Growth to these projected levels will require more residencies and more certification preparation opportunities. Residency-trained BPS specialists currently constitute slightly less than 50% of the BPS-certified population. CONCLUSION Specialization in the pharmacy profession is growing at a rapid pace. As more clinical privileges are approved, the demand for more specialized pharmacists will likely continue to increase. Data from this study document the growth of the pharmacy specialty workforce. The data and analysis can be used to estimate potential pharmacist contributions across the healthcare spectrum in clinical areas where BPS-certified pharmacists practice.
Collapse
Affiliation(s)
- Robert J Ignoffo
- University of California, San Francisco, San Francisco, CA, and Touro University California, Vallejo, CA, USA
| | | | | |
Collapse
|
2
|
Ignoffo RJ, Knapp K. Value of Oncology Pharmacists in the Oncology Health Care Workforce. JAMA Oncol 2020; 6:1120-1121. [DOI: 10.1001/jamaoncol.2020.1288] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Affiliation(s)
- Robert J. Ignoffo
- University of California, San Francisco
- Touro University California, Vallejo, California
| | | |
Collapse
|
3
|
Ignoffo RJ, Knapp KK, Seung A, Brown V, Hough S, Rieband G, Dang TO, Palumbo A, Urmanski A. Trends in the delivery of care to oncology patients in the United States: Emphasis on the role pharmacists on the healthcare team. J Oncol Pharm Pract 2020; 27:5-13. [DOI: 10.1177/1078155220907674] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Objective The purpose of this study was to identify trends in oncology care that allow one to forecast workforce supply and demand, the training and skills needed by the oncology pharmacist for the likely future of oncology care. Methods Interviews were conducted with experienced oncology pharmacists in leadership roles at 20 organizations balanced by geographic region and type of practice site (academic or community/ambulatory). Results were analyzed using descriptive statistics and theme identification. Results Practice sites differed widely in numbers of patient visits, practitioner/patient ratios, residency program presence, and other structural features. Despite this, the majority reported an expectation of growth in cancer patients, oncology physicians, oncology pharmacists, pharmacy technicians, oncology nurses, and advanced practice practitioners in the next two to five years. Fifty percent of sites currently support Post Graduate Year 2 (PGY2) oncology residencies. At least 50% reported routine pharmacist involvement in 12 clinical functions. More future involvement was predicted for immunotherapy (80%) and oral oncolytic therapy (90%). Interprofessional involvement was reported for a broad variety of practice-related committees and patient education teams. Limited pharmacist involvement in credentialing, quality measurement, and value-based reimbursement systems was found. Conclusion Anticipated increases in demand for oncology pharmacists strongly suggest the need for more PGY2 oncology residency programs and on-the-job oncology training programs. Oncology pharmacists are currently involved in many clinical and administrative functions including multidisciplinary management. While a core set of clinical functions has been identified, oncology pharmacists must prepare for the increased use of oral oncology agents and immunotherapy. Pharmacist involvement in value-based reimbursement and other data-based quality outcome measurements should be increased to optimize involvement in team-based patient care.
Collapse
Affiliation(s)
- Robert J Ignoffo
- Department of Clinical Pharmacy, University of California, San Francisco, CA, USA
- Touro University California, Mare Island, Vallejo, CA, USA
| | | | - Amy Seung
- Pharmacy Times Continuing Education, Cranbury, NJ, USA
| | - Victoria Brown
- Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, USA
| | - Shannon Hough
- Department of Pharmacy Services and Clinical Sciences, Michigan Medicine and University of Michigan College of Pharmacy, Ann Arbor, MI, USA
| | | | - Thu Oanh Dang
- Department of Pharmacy, Massachusetts General Hospital, Boston, MA, USA
| | - Alison Palumbo
- Department of Pharmacy Services, Oregon Health & Science University, Portland, OR, USA
- Department of Pharmacy Services, Oregon State University/OHSU College of Pharmacy, Corvallis, OR, USA
| | - Angela Urmanski
- Froedtert & The Medical College of Wisconsin, Milwaukee, WI, USA
| |
Collapse
|
4
|
Abstract
Purpose. The objectives of this study were (1) to describe the usage of topical oral solutions in patients experiencing chemotherapy-induced oral mucositis (CIOM); and (2) to survey the care of oral mucositis provided to patients by clinical oncology pharmacists in institutional settings. Methods. Surveys were distributed to institutional pharmacists in the US, who were asked to provide the components of their ‘magic mouthwash’. Other questions included whether an institutional mucositis management guideline is available and what is the involvement of clinical pharmacy in mucositis care. Results. Forty institutions returned surveys during the study period. The top five ingredients used to compound the magic mouthwash are diphenhydramine, viscous lidocaine, magnesium hydroxide/aluminum hydroxide, nystatin and corticosteroids. Most institutions administer the mouthwash every 4 hours (36%) or every 6 hours (36%). Of the surveyed institutions, 33% currently possess guidelines for the management of CIOM. Conclusions. Most institutions in the country formulate their topical solution, or magic mouthwash, with a variety of ingredients. There is a need to standardize the ingredients used to compound the magic mouthwash, in order to fully evaluate the efficacy of the solution to manage CIOM.
Collapse
Affiliation(s)
- Alexandre Chan
- Department of Clinical Pharmacy, University of California, San Francisco, 94143-0622, USA.
| | | |
Collapse
|
5
|
Abstract
This paper presents an overview of new information on clinically relevant drug-drug interactions, particular focuses on negative drug interactions in oncology. We have generated a concise table of drug-drug interactions that provides a synopsis of the clinical outcome of the interaction along with a recommendation for management. We have also generated other tables that describe specific interactions with methotrexate and dosing guidelines for cytotoxic drugs in the presence of renal or hepatic dysfunction. Since warfarin is one of the non-anticancer drugs that is commonly used in cancer patients for the treatment and prevention of venous thromboembolism, its interactions with other anticancer drugs that have been reported in literatures were also reviewed in this paper. In general, drug interactions observed in cancer patients may be categorized into pharmacokinetic, pharmacodynamic and pharmaceutic interactions. Pharmacokinetic interactions involve one drug altering the absorption, distribution, metabolism, or excretion of another drug. Interpatient variability in the pharmacokinetic profile of many anticancer agents often complicates the predictability of the antitumor response and toxicities. Among four pharmacokinetic characteristics, drug interactions involving hepatic metabolism is probably the most common and important mechanism responsible for oncologic drug interactions. For example, several anticancer drugs including taxanes, vinca alkaloids, and irinotecan are known to be metabolized by cytochrome CYP3A4. Enzyme-inducing anticonvulsants have been shown to significantly decrease the plasma levels of these anticancer drugs, thereby compromising the anti-tumor effects. N ephrotoxicity or changes in hepatic function caused by some anticancer drugs (e.g., cisplatin, asparaginase) may also have an impact on the pharmacokinetics of the interacting agents. Pharmacodynamic interactions may occur when two or more drugs acting at a common receptor-binding site impact on the pharmacologic action of the object drug, without influencing the pharmacokinetics of each interacting agent. In clinical setting, a decrease of antitumor efficacy was observed in breast cell lines when gemcitabine or vinorelbine were used in combination with paclitaxel. On the other hand, a decreased incidence of thrombocytopenia was seen in patients receiving combination of carboplatin and palcitaxel compared to those receiving carboplatin alone. The third type of drug-drug interaction is known as pharmaceutic interaction. When one drug may alter the physical or chemical compatibility of another drug that utlimately leads to a change in appearance of the solution or a decrease of effectiveness of the drug due to drug inactivation or degradation.
Collapse
Affiliation(s)
- Masha S H Lam
- Department of Clinical Pharmacy, Shands at the University of Florida, Gainesville, FL 32610, USA
| | - Robert J Ignoffo
- School of Pharmacy, Department of Clinical Pharmacy, University of California, San Francisco 94901-6022, USA
| |
Collapse
|
6
|
Abstract
Purpose. The primary objective of this paper is to discuss pharmaceutical care of the oncology patient in the context of recent recommendations made by the Joint Commission on Accreditation of Healthcare Organizations (JCAHO) and recent changes in Health Care Reform. Data Sources. We reviewed the literature through a MEDLINE search from 1985 to 1995. We searched the following terms: pharmaceutical care, cancer, patient, and pharmacist. We restricted the search to the English language. We also have incor porated several of our practice guidelines as examples of tools that can be used in the implementation of pharmaceutical care. We also focused on areas that the JCAHO guidelines specify as important pharma ceutical care issues in the cancer patient. Data Extraction. Within the framework of drug prescribing, drug administration, drug monitoring, and patient education, we have provided interven tions that may potentially improve outcomes in can cer patients. Data Synthesis. The advent of managed care will require that the pharmacist be more involved in the care and management of the cancer patient. This activity will necessitate that the pharmacist document the impact of interventions on patient outcomes. Although tumor response and survival are classic outcomes that are assessed in the cancer patient, other outcome indicators may be used to evaluate interventions made by the pharmacist. Conclusions. This review offers strategies for implementing pharmaceutical care in the cancer pa tient. Because we did not present study results on patient outcomes, it is unknown which of these proposed pharmacist interventions are important fac tors in the implementation of pharmaceutical care in this patient population. Although pharmaceutical care is the new paradigm in pharmacy practice, we must perform prospective studies to determine its value to the cancer community.
Collapse
Affiliation(s)
- Robert J. Ignoffo
- University of California, Division of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California
| | - Reginald King
- Hahnemann Medical Center, Philadelphia, Pennsylvania
| |
Collapse
|
7
|
Abstract
In summary, there are several ways to manage chronic pain with pharmacologic agents. The clinician should consider adjunctive agents such as antidepressants, stimulants, and antianxiety drugs as well as the standard narcotic analgesics. It is important to consider various modalities in treating the patient. A greater likelihood of successful pain control will be realized if the clinician determines a patient's pain pattern and the factors that appear to impact upon the pain cycle. With these aspects in mind, the rational application of these various analgesics will bring about the eventual goal, preventing of severe, agonizing pain.
Collapse
|
8
|
Affiliation(s)
- Robert J. Ignoffo
- Touro University, and Clinical Professor Emeritus, University of California at San Francisco, 521 Parnassus Avenue, UCSF Box 0622, Room C-152, San Francisco, CA 94143
| |
Collapse
|
9
|
Ettinger DS, Bierman PJ, Bradbury B, Comish CC, Ellis G, Ignoffo RJ, Kirkegaard S, Kloth DD, Kris MG, Lim D, Markiewicz MA, McNulty R, Nabati L, Todaro B, Urba S, Yowell S. Antiemesis. J Natl Compr Canc Netw 2007; 5:12-33. [PMID: 17239323 DOI: 10.6004/jnccn.2007.0004] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
For the most recent version of the guidelines, please visit NCCN.org
Collapse
|
10
|
Abstract
PURPOSE The pharmacology, pharmacokinetics, preclinical and clinical experience to date, and clinical concerns in monitoring patients receiving bevacizumab, recombinant humanized monoclonal antibody to vascular endothelial growth factor (VEGF), are described. SUMMARY Preclinical research revealed that bevacizumab specifically inhibits VEGF, has activity in multiple cancer cell lines, and is synergistic with several cancer chemotherapeutic agents. In humans, bevacizumab has a long half-life, allowing intravenous administration once every two to three weeks. Dose-limiting toxicities, the formation of antibodies to bevacizumab, and problems with wound healing after surgery have not been observed in clinical trials. A phase II study of bevacizumab in combination with 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer showed promising results (i.e., therapeutic response rate and disease-free progression of survival), although a clear dose-response relationship was not demonstrated and concerns were raised about the potential for thromboembolic events, bleeding, hypertension, and proteinuria. In a phase III study in patients with refractory metastatic breast cancer, bevacizumab doubled the response rate from capecitabine but it did not affect survival. First-line use of bevacizumab with irinotecan, orouracil, and leucovorin produced significant improvements in response rate, duration of response, and survival in a phase III study of patients with metastatic colorectal cancer. Bevacizumab was associated with hypertension, which was readily managed with mild antihypertensive agents, and possibly with gastrointestinal (GI) perforation, but not with serious bleeding, thromboembolism, or proteinuria. Nevertheless, patients receiving bevacizumab should be monitored for GI perforation, bleeding, thromboembolism, hypertension, and proteinuria, especially if they have a condition that predisposes them to these problems (e.g., a history of unusual bleeding or clotting, hypertension, or proteinuria; use of anticoagulants or other medications that affect clotting or coagulation). CONCLUSION In clinical trials, bevacizumab has shown promise in promoting synergism with other chemotherapeutic agents in the treatment of various cancers.
Collapse
Affiliation(s)
- Robert J Ignoffo
- University of California-San Francisco, 1327 Grand Avenue, San Rafael, CA 94901-2232, USA.
| |
Collapse
|
11
|
Beney J, Devine EB, Chow V, Ignoffo RJ, Mitsunaga L, Shahkarami M, McMillan A, Bero LA. Effect of telephone follow-up on the physical well-being dimension of quality of life in patients with cancer. Pharmacotherapy 2002; 22:1301-11. [PMID: 12389880 DOI: 10.1592/phco.22.15.1301.33480] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To evaluate the effect of telephone follow-up on the physical well-being dimension of health-related quality of life in patients with cancer. DESIGN Randomized, controlled trial. SETTING Public teaching hospital. PATIENTS One hundred fifty patients with cancer who were discharged to home from the hospital. INTERVENTION Patients received a telephone follow-up call 48-72 hours after discharge. Information was solicited regarding drug-related (and other) problems. Problems were addressed, and advice and support were given. MEASUREMENTS AND MAIN RESULTS Analysis of variance revealed no differences in the physical well-being dimension of health-related quality of life between patients who received telephone follow-up and a control group who did not. Sixty-eight percent of the follow-up group and 40% of the control group (p = 0.007) reported having had at least one contact with a health professional. CONCLUSION One possible explanation for the lack of effect of the intervention is that high-risk patients in the control group received a similar intervention from other health care professionals. We suggest that telephone follow-up be coordinated among health professionals.
Collapse
Affiliation(s)
- Johnny Beney
- Institut Central des Hŏpitaux Valaisans, Sion Switzerland.
| | | | | | | | | | | | | | | |
Collapse
|
12
|
Affiliation(s)
- M S Lam
- School of Clinical Pharmacy, University of California, San Francisco, California, USA
| | | |
Collapse
|
13
|
Affiliation(s)
- J Schwenka
- University of California, San Francisco, California, USA
| | | |
Collapse
|
14
|
Abstract
The evolution of and rationale for fluorouracil-based strategies in the treatment of metastatic colorectal cancer are discussed, and the role of the new oral fluoropyrimidines is described. Although fluorouracil is one of the most widely used drugs in the United States for colorectal, head and neck, bladder, and breast cancer, response rates and survival times have been disappointing. Dihydropyrimidine dehydrogenase (DPD), a rate-limiting enzyme in the catabolism of fluorouracil, indirectly determines the drug's anticancer efficacy by regulating the availability of fluorouracil for anabolism. Recently, investigators have identified at least five compounds -capecitabine, UFT (tegafur plus uracil), eniluracil, S-1, and BOF-A2-that inhibit, destroy, inactivate, or bypass DPD's activity. Capecitabine, a prodrug of fluorouracil, circumvents DPD. UFT, S-1, and BOF-A2 contain prodrugs of fluorouracil in combination with compounds that alter DPD's activity. Fluorouracil must be administered in combination with eniluracil, an inactivator of DPD. These compounds, classified as fluoropyrimidines, can be administered orally. Oral fluoropyrimidines appear to be at least as active against metastatic colorectal cancer as conventionally administered intravenous fluorouracil, with significantly less toxicity, improved quality of life, and less expense. New oral fluoropyrimidines may ultimately provide enhanced antitumor activity to fluorouracil-containing regimens for advanced colorectal cancer.
Collapse
Affiliation(s)
- R J Ignoffo
- School of Pharmacy, University of California at San Francisco, 94143-0622, USA.
| |
Collapse
|
15
|
Affiliation(s)
- R J Ignoffo
- Clinical Professor of Pharmacy and Oncology, University of San Francisco, CA, USA
| |
Collapse
|
16
|
Affiliation(s)
- Y F Hui
- University of California, San Francisco, USA
| | | |
Collapse
|
17
|
Hui YF, Ignoffo RJ. Dolasetron. A new 5-hydroxytryptamine3 receptor antagonist. Cancer Pract 1997; 5:324-8. [PMID: 9341357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Affiliation(s)
- Y F Hui
- University of California, San Francisco, USA
| | | |
Collapse
|
18
|
|
19
|
Hui YF, Ignoffo RJ. Docetaxel in anthracycline-resistant metastatic breast cancer. Cancer Pract 1997; 5:124-127. [PMID: 9110651] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Docetaxel is a taxane that disrupts the equilibrium in the polymerization and depolymerization of microtubules, thus inhibiting cell growth. This agent is indicated for the treatment of anthracycline-resistant metastatic breast cancer. The dose-limiting adverse effect is neutropenia, but febrile neutropenia is uncommon. Like paclitaxel, docetaxel is very active in patients with both chemotherapy-resistant and refractory metastatic breast cancer. Although the mechanism of action, spectrum of activity, and side effect profile of this agent are similar to those of paclitaxel, docetaxel may be efficacious in patients with metastatic breast cancer who have become resistant or refractory to paclitaxel therapy. However, more studies are warranted before the role of docetaxel is defined in patients with paclitaxel-resistant breast cancer.
Collapse
Affiliation(s)
- Y F Hui
- Department of Clinical Pharmacy, University of California, San Francisco, USA
| | | |
Collapse
|
20
|
Linsky KF, Ignoffo RJ. Liposomal doxorubicin. Cancer Pract 1996; 4:288-90. [PMID: 9004577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Affiliation(s)
- K F Linsky
- Department of Clinical Pharmacy, University of California, San Francisco, USA
| | | |
Collapse
|
21
|
|
22
|
Chan BM, Ignoffo RJ. Vinorelbine tartrate. Cancer Pract 1995; 3:320-3. [PMID: 7663552] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
|
23
|
Ignoffo RJ. Granisetron. Cancer Pract 1994; 2:229-231. [PMID: 8055027] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
Granisetron is the second agent in the 5-HT3 receptor antagonist class to be approved for the prophylaxis of acute emesis caused by cancer chemotherapy. It is equally effective to ondansetron as a first-line agent in the prevention of acute chemotherapy-induced emesis and has a similar low toxicity profile. Granisetron will be marketed in early 1994, according to SmithKline Beecham. Additional studies will be needed to determine the role of granisetron in the current management of chemotherapy-induced emesis.
Collapse
|
24
|
Ignoffo RJ. Chemoprotectants in oncology. Cancer Pract 1994; 2:157-9. [PMID: 8055018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
|
25
|
Ignoffo RJ, Kim LE. Erythromycin and cyclosporine drug interaction. DICP 1991; 25:30-1. [PMID: 2008784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/29/2022]
Affiliation(s)
- R J Ignoffo
- Division of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 94143
| | | |
Collapse
|
26
|
Forni P, Ignoffo RJ. Error in Cancer Chemotherapy Protocols. Clin Pharm 1990; 9:14. [PMID: 2302927] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
|
27
|
Forni P, Ignoffo RJ. Error in Cancer Chemotherapy Protocols. Am J Health Syst Pharm 1989. [DOI: 10.1093/ajhp/46.12.2463b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- Peter Forni
- Pharmadex Company 209 Caledonia Street Sausalito, CA 94965
| | - Robert J. Ignoffo
- University of California Medical Center Division of Clinical Pharmacy, Box 0622 San Francisco, CA 94143
| |
Collapse
|
28
|
Hohn DC, Stagg RJ, Friedman MA, Hannigan JF, Rayner A, Ignoffo RJ, Acord P, Lewis BJ. A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 1989; 7:1646-54. [PMID: 2530317 DOI: 10.1200/jco.1989.7.11.1646] [Citation(s) in RCA: 349] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/01/2023] Open
Abstract
In 1983, the Northern California Oncology Group (NCOG) instituted a randomized trial of intravenous (IV) versus intraarterial (IA) floxuridine (FUDR) administered via an implantable pump for patients with colorectal cancer metastatic to the liver. The study objectives were to compare the hepatic response rate, time to hepatic progression, and toxicity for the two treatment arms. The study design, which allowed patients failing IV FUDR to crossover to the IA arm, prevents a meaningful comparative analysis of survival. Patients with liver-only metastases (N = 143) were randomized, 76 to the IV arm and 67 to the IA arm, and 115 patients (65 IV, 50 IA) were fully evaluable. Of the 65 patients in the IV arm, 28 crossed over to IA treatment after failing IV FUDR. The dose-limiting toxicity of IV FUDR was diarrhea, whereas biliary toxicity limited both the dose and duration of IA FUDR therapy. Of the first 25 patients treated with IA FUDR at a dose of .3 mg/kg/day, 10 developed radiographically evident biliary strictures, and three developed permanent jaundice. With reduction of the initial IA FUDR dose to .2 mg/kg/day, and adoption of a policy of early dosage reduction, treatment interruption, or termination of therapy for persistent elevations in alkaline phosphatase, only two further cases of serious biliary toxicity occurred. However, 26 of the 50 IA FUDR patients ultimately had therapy terminated because of drug toxicity rather than disease progression. When compared with systemic infusion, infusion into the hepatic artery greatly enhanced the antitumor activity of FUDR against colorectal liver metastases. Although biliary toxicity is the most serious limitation of this form of therapy, biliary stricture and jaundice usually can be averted through careful monitoring of liver enzymes and early dosage reduction.
Collapse
Affiliation(s)
- D C Hohn
- Cancer Research Institute, University of California, San Francisco
| | | | | | | | | | | | | | | |
Collapse
|
29
|
Ignoffo RJ, Forni P. Correction: Cancer Chemotherapy Protocols and dose of chlorambucil. Ann Intern Med 1989; 111:543. [PMID: 2774383 DOI: 10.7326/0003-4819-111-6-543_1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
|
30
|
Abstract
Toxicities and complications were prospectively analyzed in patients with liver metastases receiving hepatic intra-arterial (IA) and systemic intravenous (IV) floxuridine (FUDR) with the Infusaid (Intermedics-Infusaid Corp., Norwood, MA) implantable pump. Among 55 patients treated with IA FUDR (0.3-0.1 mg/kg/day X 14, every 28 days), elevations in liver enzyme values, not attributable to disease progression, developed in 96% of patients. Serious biliary toxicity occurred in 31 patients (56%). In 16, biliary sclerosis was documented radiographically and was diagnosed clinically in 15 additional patients. Ten patients were hospitalized for biliary toxicity, including five who required cholecystectomy for acalculous cholecystitis. Because of the high reported incidence of serious gastroduodenal toxicity after IA FUDR infusion, our procedure for hepatic arterial cannulation was designed to eliminate misperfusion of the stomach and duodenum with drug; none of our patients experienced FUDR-associated gastroduodenal ulceration or bleeding. Cyclic IV FUDR (0.05-0.15 mg/kg/day X 14, every 28 days) was administered to 31 participants of the Northern California Oncology Group trial (3L-82-1) of IV versus IA FUDR. Dose-limiting toxicity was diarrhea. Serious toxicities were: protracted diarrhea (three), dermatitis (two), tear duct stenosis (two), and stomatitis (two). Three patients were hospitalized for toxicity. No hematologic or biliary toxicity occurred. The optimal route for treatment of hepatic metastases with continuous FUDR infusion has not yet been established. Systemic IV infusion has low morbidity, but preliminary response data need to be substantiated in controlled clinical trials before there can be widespread clinical application. High response rates for IA infusion have been previously documented. Morbidity due to acalculous cholecystitis and gastroduodenal ulceration can now be avoided. Despite significant progress in characterization of hepatobiliary toxicity, it remains dose-limiting. Continuous IA FUDR infusion should remain under the aegis of dedicated treatment centers until standardized protocols with diminished toxicity are established.
Collapse
|
31
|
Abstract
Toxicities and complications were prospectively analyzed in patients with liver metastases receiving hepatic intra-arterial (IA) and systemic intravenous (IV) floxuridine (FUDR) with the Infusaid (Intermedics-Infusaid Corp., Norwood, MA) implantable pump. Among 55 patients treated with IA FUDR (0.3-0.1 mg/kg/day X 14, every 28 days), elevations in liver enzyme values, not attributable to disease progression, developed in 96% of patients. Serious biliary toxicity occurred in 31 patients (56%). In 16, biliary sclerosis was documented radiographically and was diagnosed clinically in 15 additional patients. Ten patients were hospitalized for biliary toxicity, including five who required cholecystectomy for acalculous cholecystitis. Because of the high reported incidence of serious gastroduodenal toxicity after IA FUDR infusion, our procedure for hepatic arterial cannulation was designed to eliminate misperfusion of the stomach and duodenum with drug; none of our patients experienced FUDR-associated gastroduodenal ulceration or bleeding. Cyclic IV FUDR (0.05-0.15 mg/kg/day X 14, every 28 days) was administered to 31 participants of the Northern California Oncology Group trial (3L-82-1) of IV versus IA FUDR. Dose-limiting toxicity was diarrhea. Serious toxicities were: protracted diarrhea (three), dermatitis (two), tear duct stenosis (two), and stomatitis (two). Three patients were hospitalized for toxicity. No hematologic or biliary toxicity occurred. The optimal route for treatment of hepatic metastases with continuous FUDR infusion has not yet been established. Systemic IV infusion has low morbidity, but preliminary response data need to be substantiated in controlled clinical trials before there can be widespread clinical application. High response rates for IA infusion have been previously documented. Morbidity due to acalculous cholecystitis and gastroduodenal ulceration can now be avoided. Despite significant progress in characterization of hepatobiliary toxicity, it remains dose-limiting. Continuous IA FUDR infusion should remain under the aegis of dedicated treatment centers until standardized protocols with diminished toxicity are established.
Collapse
|
32
|
Ignoffo RJ, Friedman MA, Gribble M, Hannigan J, Reynolds R, Yu KP, Schiff S, Congdon JE. Phase II study of sequential methotrexate and 5-FU plus mitomycin and leucovorin in patients with disseminated large bowel cancer: a Northern California Oncology Group study. Cancer Treat Rep 1984; 68:983-8. [PMID: 6611204] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
Sequential methotrexate (MTX) and 5-FU plus leucovorin and mitomycin (MMC) was given to 52 patients with disseminated, measurable colorectal cancer. Complete and partial responses were seen in 19 of 49 (39%) evaluable patients. Nine additional patients achieved a minimal response. Median overall survival was 8.8 months, while that for patients objectively responding was 13.6 months. This study utilized a MTX exposure period of 12 hours prior to 5-FU. In comparison to other trials utilizing sequential MTX and 5-FU, the addition of MMC to the regimen may improve the response rate but increases the incidence of adverse effects, particularly myelosuppression and renal toxicity. This phase II trial suggests that sequential MTX and 5-FU plus leucovorin and MMC is an active combination therapy and warrants further comparative trial in patients with large bowel cancer.
Collapse
|
33
|
Abstract
Hepatic metastases of colorectal origin are resistant to radiation and immunotherapy. Traditional intravenous chemotherapy produces responses in 10% to 30% of patients, and surgical resection is feasible in approximately 20% of patients who have a solitary or unilobar lesion. Infusion of cytotoxic agents into the hepatic artery, introduced 2 decades ago, is the most promising form of therapy for unresectable hepatic metastases. Fluorouracil, floxuridine, and mitomycin have been most commonly administered by hepatic arterial infusion. The recent development of a totally implantable pump has allowed prolonged ambulatory infusion of chemotherapeutic agents into the hepatic artery. We review the recent data on the pharmacology, therapeutic outcome, administration techniques, and complications of hepatic arterial chemotherapy. Future trials in this area should use uniform stratification variables and standardized criteria for evaluating response, time to progression, and survival.
Collapse
|
34
|
Smith RA, Pons VG, Ignoffo RJ. Intravenous antibiotics, avoiding complications. J Oral Med 1984; 39:22-32. [PMID: 6585492] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
|
35
|
Hattersley PG, Mitsuoka JC, Ignoffo RJ, King JH, Musallam NA. Adjusting heparin infusion rates from the initial response to activated coagulation time. Drug Intell Clin Pharm 1983; 17:632-4. [PMID: 6617481 DOI: 10.1177/106002808301700904] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
Abstract
A mathematical description of the dose-response curve of heparin to the activated coagulation time is applied retrospectively to 20 patients treated with continuous heparin infusion. The adjusted heparin dose was compared with a calculated prediction using the theoretical mathematical model. The main actual dose was 28 U/kg/h, and the mean predicted dose was 25.8 U/kg/h. The correlation coefficient was 0.862 (p3 0.05). These data are used to develop a dosing adjustment chart. Special considerations prior to using the calculation or dosing adjustment chart are discussed. The use of this model may allow the clinician to determine more rapidly a therapeutic heparin dosage than previous empiric approaches.
Collapse
|
36
|
Ignoffo RJ. Does etoposide have curative potential? Clin Pharm 1983; 2:167. [PMID: 6309470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
37
|
Abstract
The pharmacokinetics of moderate doses of methotrexate administered via the hepatic artery were studied in ten patients with cancer metastatic to the liver. Intra-arterial methotrexate showed two-compartment characteristics with a clearance of 79 ml/min/m2 and an apparent volume of distribution of 21.2 l/m2 body surface area. The average half-life of the early phase was 1.9 h and the terminal half-life was 14.4 h. The data were not different from those observed in similar patients after IV administration of equivalent doses of methotrexate.
Collapse
|
38
|
|
39
|
|
40
|
Ignoffo RJ, Korman N. Correction of Errors in Applied Therapeutics for Clinical Pharmacists. Am J Health Syst Pharm 1979. [DOI: 10.1093/ajhp/36.8.1044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Robert J. Ignoffo
- School of Pharmacy, University of California, San Francisco, OA 94143
| | - Nancy Korman
- School of Pharmacy, University of California, San Francisco, OA 94143
| |
Collapse
|
41
|
|
42
|
Tong TG, Ignoffo RJ. Glaucoma. J Am Pharm Assoc 1972; 12:520-3 passim. [PMID: 5069355] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
|